Calcium signaling dysfunction in schizophrenia: A unifying approach

Brain Research Reviews

Volumn 43, Issue 1, 2003, Pages 70-84

  Lidow, Michael S ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Ca 2+ homeostasis; Ca2+ binding proteins; Free intracellular Ca2+; Hypothesis of schizophrenia

Indexed keywords

CALBINDIN; CALCIUM; CYCLIC AMP; FATTY ACID; GLYCOGEN SYNTHASE KINASE 3BETA; HYBRID PROTEIN; N ETHYLMALEIMIDE; NEUROMODULIN; PARVALBUMIN; PHOSPHOLIPASE A2; PROTEIN KINASE C; REELIN; SYNAPSIN I; SYNAPSIN II; SYNAPTOPHYSIN; VISININ;

BIOAVAILABILITY; BIOCHEMISTRY; CALCIUM CELL LEVEL; CALCIUM SIGNALING; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; MITOCHONDRION; MYELINATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 0141853757     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(03)00203-0     Document Type: Review

References (245)

1. Akbarian S., Kim J.J., Potkin S.G., Hetrick W.P., Bunney W.E. Jr., Jones E.G. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch. Gen. Psychiatry. 53:1996;425-436.
2. Akira S., Snyder S. Schizophrenia: diverse approaches to complex disease. Science. 296:2002;692-695.
3. Albert K.A., Hemmings H.C. Jr., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., Cotman C.W., Bunney W.E., Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry. 59:2002;705-712.
4. Alexander P.E., Jackson A.H. Calcium and magnesium: relationship to schizophrenia and neuroleptic-induced extrapyramidal symptoms. Alexander P.E. Electrolytes and Neuropsychiatric Disorders. 1981;247-275 MIT Press, Lancaster.
5. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 349:1997;1730-1734.
6. Arnold S.E. Neurodevelopmental abnormalities in schizophrenia: insights from neuropathology. Dev. Psychopathol. 11:1999;439-456.
7. Bacic F., Uematsu S., McCarron R.M., Spatz M. Dopaminergic receptors linked to adenylate cyclase in human cerebromicrovascular endothelium. J. Neurochem. 57:1991;1774-1780.
8. Bartzokis G. Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology. 27:2002;672-683.
9. Batuecas A., Pereira R., Centeno C., Pulido J.A., Hernandez M., Bollati A., Bogonez E., Satrustegui J. Effects of chronic nimodipine on working memory of old rats in relation to defects in synaptosomal calcium homeostasis. Eur. J. Pharmacol. 350:1998;141-150.
10. Beasley B., Cotter D., Khan N., Pollard C., Sheppard P., Varndell I., Lovestone S., Anderton B., Everall I. Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci. Lett. 302:2001;117-120.
11. Bellomo G., Mirabelli F. Oxidative stress injury studied in isolated intact cells. Mol. Toxicol. 1:1987;281-293.
12. Benes F.M., Davidson J., Bird E.D. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch. Gen. Psychiatry. 43:1986;31-35.
13. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry. 48:1991;996-1001.
14. Benes F.M., Kwok E.W., Vincent S.L., Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry. 44:1998;88-97.
15. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 25:2001;1-27.
16. 2+/calmodulin-dependent protein kinase II is a binding protein for synapsin I. Nature. 359:1992;417-420.
17. Benowitz L.I., Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 20:1997;84-91.
18. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J. Neurochem. 83:2002;1241-1251.
19. Berger G.E., Wood S.J., Pantelis C., Velakoulis D., Wellard R.M., McGorry P.D. Implications of lipid biology for the pathogenesis of schizophrenia. Aust. NZ J. Psychiatry. 36:2002;355-366.
20. Bernstein H.G., Krell D., Braunewell K.H., Baumann B., Gundelfinger E.D., Diekmann S., Danos P., Bogerts B. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J. Neurocytol. 30:2001;661-670.
21. Bernstein H.G., Braunewell K.H., Spilker C., Danos P., Baumann B., Funke S., Diekmann S., Gundelfinger E.D., Bogerts B. Hippocampal expression of the calcium sensor protein visinin-like protein-1 in schizophrenia. Neuroreport. 13:2002;393-396.
22. Bersani G., Iannitelli A., Fiore M., Angelucci F., Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med. Hypotheses. 55:2000;199-207.
23. Binda A.V., Kabbani N., Lin R., Levenson R. D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol. Pharmacol. 62:2002;507-513.
24. Bird M.M., Owen A. The effect of calcium ionophore A23187 on neurites from embryonic mouse spinal cord explants in culture. J. Electron. Microsc. (Tokyo). 49:2000;379-386.
25. Birnbaum S.G., Davis D., Gobeske K., Taylor J.R., Arnsten A.F.T. The intracellular signaling mechanisms mediating stress-induced prefrontal cortex dysfunction in rats. Am. Soc. Neurosci. Abs. 27:2001;1404.
26. Blennow K., Bogdanovic N., Gottfries C.G., Davidsson P. The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia. J. Mol. Neurosci. 13:1999;101-109.
27. Bofill-Cardona E., Kudlacek O., Yang Q., Ahorn H., Freissmuth M., Nanoff C. Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. J. Biol. Chem. 275:2000;32672-32680.
28. Boxer A.L., Moreno H., Rudy B., Ziff E.B. FGF-2 potentiates Ca(2+)-dependent inactivation of NMDA receptor currents in hippocampal neurons. J. Neurophysiol. 82:1999;3367-3377.
29. Brandon N.J., Delmas P., Kittler J.T., McDonald B.J., Sieghart W., Brown D.A., Smart T.G., Moss S.J. GABAa receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway. J. Biol. Chem. 275:2000;38856-38862.
30. Braunewell K.H., Gundelfinger E.D. Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Cell. Tissue Res. 295:1999;1-12.
31. Broadbelt K., Byne W., Jones L.B. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr. Res. 58:2002;75-81.
32. Browning M.D., Dudek E.M., Rapier J.L., Leonard S., Freedman R. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol. Psychiatry. 34:1993;529-535.
33. Cadet J.L., Kahler L.A. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci. Biobehav. Rev. 18:1994;457-467.
34. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R.A., Borrelli E., Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 21:2001;5110-5120.
35. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:2001;237-260.
36. Castner S.A., Goldman-Rakic P.S. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology. 20:1999;10-28.
37. Cepeda C., Levine M.S. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20:1998;1-18.
38. 2+ increases in both the cytoplasm and nucleoplasm of rat cerebellar granule cells. J. Physiol. 537:2001;497-510.
39. Cheng B., Mattson M.P. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res. 640:1994;56-67.
40. Choi D.Y., Toledo-Aral J.J., Segal R., Halegoua S. Sustained signaling by phospholipase C-gamma mediates nerve growth factor-triggered gene expression. Mol. Cell. Biol. 21:2001;2695-2705.
41. Climent E., Sancho-Tello M., Minana R., Barettino D., Guerri C. Astrocytes in culture express the full-length Trk-B receptor and respond to brain derived neurotrophic factor by changing intracellular calcium levels: effect of ethanol exposure in rats. Neurosci. Lett. 7:2000;53-56.
42. Copolov D., Crook J. Biological markers and schizophrenia. Aust. NZ J. Psychiatry. 34:(Suppl.):2000;S108-A112.
43. Costa E., Davis J., Grayson D.R., Guidotti A., Pappas G.D., Pesold C. Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. Neurobiol. Dis. 8:2001;723-742.
44. Daniel D.G., Berman K.F., Weinberger D.R. The effect of apomorphine on regional cerebral blood flow in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1:1989;377-384.
45. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., Bigelow L.B., Goldberg T.E., Berman K.F., Kleinman J.E. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J. Neurosci. 11:1991;1907-1917.
46. D'Arcangelo G., Homayouni R., Keshvara L., Rice D.S., Sheldon M., Curran T. Reelin is a ligand for lipoprotein receptors. Neuron. 24:1999;471-479.
47. Das I., Khan N.S., Puri B.K., Sooranna S.R., de Belleroche J., Hirsch S.R. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem. Biophys. Res. Commun. 212:1995;375-380.
48. Dean B., Opeskin K., Pavey G., Hill C., Keks N. Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia. J. Neural Transm. 104:1997;1371-1381.
49. Desrues L., Lamacz M., Jenks B.G., Vaudry H., Tonon M.C. Effect of dopamine on adenylate cyclase activity, polyphosphoinositide metabolism and cytosolic calcium concentrations in frog pituitary melanotrophs. J. Endocrinol. 136:1993;421-429.
50. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 33:2001;637-668.
51. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 52:2001;79-86.
52. Eastwood S.L., Harrison P.J. Hippocampal and cortical growth-associated protein-43 messenger RNA in schizophrenia. Neuroscience. 86:1998;437-448.
53. Eastwood S.L., Cairns N.J., Harrison P.J. Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex. Br. J. Psychiatry. 176:2000;236-242.
54. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14:2000;1-21.
55. Emilien G., Maloteaux J.M., Geurts M., Owen M.J. Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology. Int. J. Neuropsychopharmacol. 2:1999;197-227.
56. Emilien G., Maloteaux J.M., Geurts M., Hoogenberg K., Cragg S. Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 84:1999;133-156.
57. Ermak G., Davies K.J. Calcium and oxidative stress: from cell signaling to cell death. Mol. Immunol. 38:2002;713-721.
58. Eyles D.W., McGrath J.J., Reynolds G.P. Neuronal calcium-binding proteins and schizophrenia. Schizophr. Res. 57:2002;27-34.
59. Falkai P., Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur. Arch. Psychiatry Neurol. Sci. 236:1986;154-161.
60. Fatemi S.H., Kroll J.L., Stary J.M. Altered levels of Reelin and its isoforms in schizophrenia and mood disorders. Neuroreport. 12:2001;3209-3215.
61. Fenton W.S., Hibbeln J., Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry. 47:2000;8-21.
62. Foong J., Maier M., Barker G.J., Brocklehurst S., Miller D.H., Ron M.A. In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J. Neurol. Neurosurg. Psychiatry. 68:2000;70-74.
63. 2+ mobilization and release of acetylcholine from guinea-pig neostriatal slices. Br. J. Pharmacol. 91:1987;287-297.
64. Gabriel S.M., Haroutunian V., Powchik P., Honer W.G., Davidson M., Davies P., Davis K.L. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch. Gen. Psychiatry. 54:1997;559-566.
65. Gao W.J., Krimer L.S., Goldman-Rakic P.S. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc. Natl. Acad. Sci. USA. 98:2001;295-300.
66. Gattaz W.F., Lara D.R., Elkis H., Portela L.V., Goncalves C.A., Tort A.B., Henna J., Souza D.O. Decreased S100-beta protein in schizophrenia: preliminary evidence. Schizophr. Res. 43:2000;91-95.
67. 2+ signal transduction by members of the calpacitin protein family. J. Neurosci. Res. 58:1999;107-119.
68. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. J. Neural. Transm. Suppl. 36:1992;43-59.
69. Gibson G.E., Zhang H., Xu H., Park L.C., Jeitner T.M. Oxidative stress increases internal calcium stores and reduces a key mitochondrial enzyme. Biochim. Biophys. Acta. 1586:2001;177-189.
70. Gnegy M.E., Agrawal A., Hewlett K., Yeung E., Yee S. Repeated haloperidol increases both calmodulin and a calmodulin-binding protein in rat striatum. Mol. Brain Res. 27:1994;195-204.
71. Goff D.C., Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr. Res. 27:1997;157-168.
72. Goldman-Rakic P.S. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 6:1994;348-357.
73. Gomperts B.D., Tatham P.E.R., Kramer I.M. Signal Transduction. 2002;Academic Press, San Diego.
74. 2+ sensitivity of synaptic vesicle dopamine, gamma-aminobutyric acid, and glutamate transport systems. Neurochem. Res. 26:2001;75-81.
75. Goodman A.B., Pardee A.B. Meeting report: 'molecular neurobiological mechanisms in schizophrenia: seeking a synthesis'. Biol. Psychiatry. 48:2000;173-183.
76. Grebb J.A., Shelton R.C., Taylor E.H., Bigelow L.B. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia. Biol. Psychiatry. 21:1986;691-694.
77. Greengard P., Benfenati F., Valtorta F. Synapsin I, an actin-binding protein regulating synaptic vesicle traffic in the nerve terminal. Adv. Second Messenger Phosphoprotein Res. 29:1994;31-45.
78. Greengard P., Nairn A.C., Girault J.A., Ouimet C.C., Snyder G.L., Fisone G., Allen P.B., Fienberg A., Nishi A. The DARPP-32/protein phosphatase-1 cascade: a model for signal integration. Brain Res. Rev. 26:1998;274-284.
79. Greiner A.C., Chan S.C., Nicolson G.A. Human brain contents of calcium, copper, magnesium, and zinc in some neurological pathologies. Clin. Chim. Acta. 64:1975;211-213.
80. 2+ signal transduction by members of the calpacitin protein family. J. Neurosci. Res. 58:1999;107-119.
81. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA. 98:2001;4746-4751.
82. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 122:1999;593-624.
83. Hartigan J.A., Johnson G.V. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3β-dependent pathway. J. Biol. Chem. 274:1999;21395-21401.
84. Heizmann C.W., Fritz G., Schafer B.W. S100 proteins: structure, functions and pathology. Front. Biosci. 7:2002;d1356-d1368.
85. Hemby S.E., Ginsberg S.D., Brunk B., Arnold S.E., Trojanowski T.Q., Eberwine J.H. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch. Gen. Psychiatry. 59:2002;631-640.
86. 2+ currents and excitability via a novel PLCβ1-IP3-calcineurin-signaling cascade. J. Neurosci. 20:2000;8987-8995.
87. Hirai K., Yoshioka H., Kihara M., Hasegawa K., Sakamoto T., Sawada T., Fushiki S. Inhibiting neuronal migration by blocking NMDA receptors in the embryonic rat cerebral cortex: a tissue culture study. Dev. Brain Res. 114:1999;63-67.
88. Honer W.G., Falkai P., Chen C., Arango V., Mann J.J., Dwork A.J. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience. 91:1999;1247-1255.
89. Horrobin D.F. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot. Essent. Fatty Acids. 55:1996;3-7.
90. Hudson C., Gotowiec A., Seeman M., Warsh J., Ross B.M. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biol. Psychiatry. 46:1999;401-405.
91. Iadecola C. Regulation of the cerebral microcirculation during neural activity: is nitric oxide the missing link? Trends Neurosci. 16:1993;206-214.
92. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., Uzunov D.P., Smalheiser N.R., Davis J.M., Pandey G.N., Pappas G.D., Tueting P., Sharma R.P., Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. USA. 95:1998;15718-15723.
93. Ishii M., Inanobe A., Fujita S., Makino Y., Hosoya Y., Kurachi Y. Ca(2+) elevation evoked by membrane depolarization regulates G protein cycle via RGS proteins in the heart. Circ. Res. 89:2001;1045-1050.
94. Isokawa M. Modulation of GABAA receptor-mediated inhibition by postsynaptic calcium in epileptic hippocampal neurons. Brain Res. 810:1998;241-250.
95. Jarskog L.F., Gilmore J.H., Selinger E.S., Lieberman J.A. Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol. Psychiatry. 48:2000;641-650.
96. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
97. Jeste D.V., Lohr J.B. Hippocampal pathologic findings in schizophrenia. A morphometric study. Arch Gen. Psychiatry. 46:1989;1019-1024.
98. Jimerson D.C., Post R.M., Carman J.S., van Kammen D.P., Wood J.H., Goodwin F.K., Bunney W.E. CSF calcium: clinical correlates in affective illness and schizophrenia. Biol. Psychiatry. 14:1979;37-51.
99. Jung M.Y., Hof P.R., Schmauss C. Targeted disruption of dopamine D92) and D93) receptor genes leads to different alterations in the expression of striatal calbindin-D(2k). Neuroscience. 97:2000;495-504.
100. Kabbani N., Negyessy L., Lin R., Goldman-Rakic P., Levenson R. Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor. J. Neurosci. 22:2002;8476-8486.
101. Kaiya H. Second messenger imbalance hypothesis of schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids. 46:1992;33-38.
102. Kaneko M., Sato K., Horikoshi R., Yaginuma M., Yaginuma N., Shiragata M., Kumashiro H. Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo. Prostaglandins Leukot. Essent. Fatty Acids. 46:1992;53-57.
103. 2+- and calmodulin-dependent phosphorylation and synaptic vesicles. J. Neurosci. 19:1999;3801-3808.
104. 2+ homeostasis and possible interaction between GABAA and GABAB receptors in regulation of transmitter release in cerebellar granule neurons. J. Neurosci. Res. 39:1994;646-655.
105. Karson C.N., Griffin W.S., Mrak R.E., Husain M., Dawson T.M., Snyder S.H., Moore N.C., Sturner W.G. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol. Chem. Neuropathol. 27:1996;275-284.
106. Kassack M.U., Hofgen B., Lehmann J., Eckstein N., Quillan J.M., Sadee W. Functional screening of G protein-coupled receptors by measuring intracellular calcium with a fluorescence microplate reader. J. Biomol. Screen. 7:2002;233-246.
107. 2+ transport systems in lymphocytes. FEBS Lett. 353:1994;167-170.
108. Kinoshita M., Nukada T., Asano T., Mori Y., Akaike A., Satoh M., Kaneko S. Binding of Gα(o) N terminus is responsible for the voltage-resistant inhibition of α(1A) (P/Q-type, Ca(v)2.1) Ca(2+) channels. J. Biol. Chem. 276:2001;28731-28738.
109. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J. Psychopharmacol. 11:1997;123-131.
110. Knable M.B., Torrey E.F., Webster M.J., Bartko J.J. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res. Bull. 55:2001;651-659.
111. Koh P.O., Undie A.S., Kabbani N., Levenson R., Goldman-Rakic P.S., Lidow M.S. Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc. Natl. Acad. Sci. USA. 100:2003;313-317.
112. Koh P.O., Bergson C., Undie A.S., Goldman-Rakic P.S., Lidow M.S. Upregulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia. Arch. Gen. Psychiatry. 60:2003;311-319.
113. Kornhuber J., Lange K.W., Kruzik P., Rausch W.D., Gabriel E., Jellinger K., Riederer P. Iron, copper, zinc, magnesium, and calcium in postmortem brain tissue from schizophrenic patients. Biol. Psychiatry. 36:1994;31-34.
114. Kotecha S.A., Oak J.N., Jackson M.F., Perez Y., Orser B.A., Van Tol H.H., MacDonald J.F. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron. 35:2002;1111-1122.
115. Kozlovsky N., Belmaker R.H., Agam G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12:2002;13-25.
116. Krauss G. 2nd Edition Biochemistry of Signal Transduction and Regulation. 2001;John Wiley, New York.
117. 2+-dependent inactivation of NMDA receptors. J. Neurosci. 19:1999;1165-1178.
118. Krupp J.J., Vissel B., Thomas C.G., Heinemann S.F., Westbrook G.L. Calcineurin acts via the C-terminus of NR2A to modulate desensitization of NMDA receptors. Neuropharmacology. 42:2002;593-602.
119. 2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 16:2000;279-283.
120. Kuperberg G., Heckers S. Schizophrenia and cognitive function. Curr. Opin. Neurobiol. 10:2000;205-210.
121. Landen M., Davidsson P., Gottfries C.G., Grenfeldt B., Stridsberg M., Blennow K. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia. Biol. Psychiatry. 46:1999;1698-1702.
122. Landen M., Davidsson P., Gottfries C.G., Mansson J.E., Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr. Res. 55:2002;83-88.
123. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V., Goncalves C.A., Fonseca M., Hauck S., Souza D.O. Increased serum S100β protein in schizophrenia: a study in medication-free patients. J. Psychiatr. Res. 35:2001;11-14.
124. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q. J. Nucl. Med. 42:1998;211-221.
125. Lautermilch N.J., Spitzer N.C. Regulation of calcineurin by growth cone calcium waves controls neurite extension. J. Neurosci. 20:2000;315-325.
126. Lee A.K. Dopamine (D2) receptor regulation of intracellular calcium and membrane capacitance changes in rat melanotrophs. J. Physiol. 495:1996;627-640.
127. Lee F.J., Xue S., Pei L., Vukusic B., Chery N., Wang Y., Wang Y.T., Niznik H.B., Yu X.M., Liu F. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell. 111:2002;219-230.
128. Lejoyeux M., Maziere J.C. Could the interaction of neuroleptics with calmodulin be an 'explanation' of the psychotropic effects? Encephale. 17:1991;11-15.
129. Leonhardt W., Lange M. Antioxidative action of the novel calcium channel antagonist mibefradil on low-density lipoproteins. Eur. J. Clin. Pharmacol. 54:1998;603-607.
130. Lezcano N., Mrzljak L., Eubanks S., Levenson R., Goldman-Rakic P., Bergson C. Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein. Science. 287:2000;1660-1664.
131. Lezcano N., Bergson C. D1/D5 dopamine receptors stimulate intracellular calcium release in primary cultures of neocortical and hippocampal neurons. J. Neurophysiol. 87:2001;2167-2175.
132. Lidow M.S. General overview of contemporary antipsychotic medications. Lidow M.S. Neurotransmitter Receptors in Actions of Antipsychotic Medications. 2000;17-30 CRC Press, Boca Raton, FL.
133. Lidow M.S., Williams G.V., Goldman-Rakic P.S. The cerebral cortex: a case for a common site of action of antipsychotics. Trends Pharmacol. Sci. 19:1998;136-140.
134. Lidow M.S., Koh P.O., Arnsten A.F. D1 dopamine receptors in the mouse prefrontal cortex: immunocytochemical and cognitive neuropharmacological analyses. Synapse. 47:2003;101-108.
135. Lin R., Karpa K., Kabbani N., Goldman-Rakic P., Levenson R. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc. Natl. Acad. Sci. USA. 98:2001;5258-5263.
136. Lin X.H., Kitamura N., Hashimoto T., Shirakawa O., Maeda K. Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia. Biol. Psychiatry. 46:1999;1665-1671.
137. Loeber R.T., Sherwood A.R., Renshaw P.F., Cohen B.M., Yurgelun-Todd D.A. Differences in cerebellar blood volume in schizophrenia and bipolar disorder. Schizophr. Res. 37:1999;81-89.
138. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;463-493.
139. Mak I.T., Zhang J., Weglicki W.B. Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. Pharmacol. Res. 45:2002;27-33.
140. Marta C.B., Davio C., Pasquini L.A., Soto E.F., Pasquini J.M. Molecular mechanisms involved in the actions of apotransferrin upon the central nervous system: role of the cytoskeleton and of second messengers. J. Neurosci. Res. 69:2002;488-496.
141. Martinez-Serrano A., Borner C., Pereira R., Villalba M., Satrustegui J. Modulation of presynaptic calcium homeostasis by nitric oxide. Cell. Calcium. 20:1996;293-302.
142. Mattson M.P. Calcium as sculptor and destroyer of neural circuitry. Exp. Gerontol. 27:1992;29-49.
143. Maurer I., Zierz S., Moller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 48:2001;125-136.
144. McCutchen M.E., Bramham C.R., Pozzo-Miller L.D. Modulation of neuronal calcium signaling by neurotrophic factors. Int. J. Dev. Neurosci. 20:2002;199-207.
145. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry. 57:2000;637-648.
146. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5:2002;267-271.
147. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 22:2002;2718-2729.
148. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 28:2000;53-67.
149. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol. Psychiatry. 6:2001;293-301.
150. Mirotznik R.R., Zheng X., Stanley E.F. G-Protein types involved in calcium channel inhibition at a presynaptic nerve terminal. J. Neurosci. 20:2000;7614-7621.
151. Miyaoka T., Seno H., Ishino H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr. Res. 38:1999;1-6.
152. H.W. Moises, Human genome data analysis by an evolutionary method suggests a decrease in protein-synthesis rate as cause of schizophrenia and an increase as antipsychotic mechanism, ArXiv.org e-Pprint archive (2001) [ http://xxx.arxiv.cornell.edu/abs/cond-mat/0110189 ].
153. Moises H.W., Zoega T., Gottesman I.I. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry. 2:2002;8.
154. Moller J.R. Rapid conversion of myelin-associated glycoprotein to a soluble derivative in primates. Brain Res. 741:1996;27-31.
155. 2+ signaling complexes in polarized cells. Cell Calcium. 26:1999;173-180.
156. Murakami M., Kudo I. Phospholipase A2. J. Biochem. (Tokyo). 131:2002;285-292.
157. Nawa H., Takahashi M., Patterson P.H. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol. Psychiatry. 5:2000;594-603.
158. Nelson P.G., Fields R.D., Yu C., Neale E.A. Mechanisms involved in activity-dependent synapse formation in mammalian central nervous system cell cultures. J. Neurobiol. 21:1990;138-156.
159. Neylon C.B., Nickashin A., Tkachuk V.A., Bobik A. Heterotrimeric Gi protein is associated with the inositol 1,4,5-trisphosphate receptor complex and modulates calcium flux. Cell Calcium. 23:1998;281-289.
160. 2+-dependent interaction with calmodulin is conserved in the synapsin family: identification of a high-affinity site. Biochemistry. 36:1997;11487-11495.
161. Nikashin A.B., Neylon K.B., Bobik A., Tkachuk V.A. Regulation of inositol-1,4,5-triphosphate receptor by G(i)-protein. Ross. Fiziol. Zh. Im. IM. Sechenova. 85:1999;1011-1021.
162. Novak G., Seeman P., Tallerico T. Schizophrenia: elevated mRNA for calcium-calmodulin-dependent protein kinase IIbeta in frontal cortex. Mol. Brain Res. 82:2000;95-100.
163. Numakawa T., Yokomaku D., Kiyosue K., Adachi N., Matsumoto T., Numakawa Y., Taguchi T., Hatanaka H., Yamada M. Basic fibroblast growth factor evokes a rapid glutamate release through activation of the MAPK pathway in cultured cortical neurons. J. Biol. Chem. 277:2002;28861-28869.
164. Okada F., Crow T.J., Roberts G.W. G proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J. Neural Transm. Gen. Sect. 84:1991;147-153.
165. Okda F., Tokumitsu Y., Takahashi N., Crow T.J., Roberts G.W. Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain. J. Neural Transm. Gen. Sect. 95:1994;95-104.
166. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
167. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33:1999;523-533.
168. Palermo-Neto J. Dopaminergic system. Dopamine receptors. Psychiatr. Clin. North Am. 20:1997;705-721.
169. Paul Blum B., Mann J.J. The GABAergic system in schizophrenia. Int. J. Neuropsychopharmacol. 5:2002;159-179.
170. Perrone-Bizzozero N.I., Cansino V.V., Kohn D.T. Posttranscriptional regulation of GAP-43 gene expression in PC12 cells through protein kinase C-dependent stabilization of the mRNA. J. Cell Biol. 120:1993;1263-1270.
171. Perrone-Bizzozero N.I., Sower A.C., Bird E.D., Benowitz L.I., Ivins K.J., Neve R.L. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc. Natl. Acad. Sci. USA. 93:1996;14182-14187.
172. Pinton P., Ferrari D., Rapizzi E., Di Virgilio F., Pozzan T., Rizzuto R. A role for calcium in Bcl-2 action? Biochimie. 84:2002;195-201.
173. Plein H., Berk M. The platelet as a peripheral marker in psychiatric illness. Hum. Psychopharmacol. 16:2001;229-236.
174. Pongrac J., Middleton F.A., Lewis D.A., Levitt P., Mirnics K. Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. Neurochem. Res. 27:2002;1049-1063.
175. Popken G.J., Bunney W.E. Jr., Potkin S.G., Jones E.G. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc. Natl. Acad. Sci. USA. 97:2000;9276-9280.
176. Popov N., Matthies H. Influence of dopamine receptor agonists and antagonists on calmodulin translocation in different brain regions. Eur. J. Pharmacol. 172:1989;205-210.
177. Prince J.A., Blennow K., Gottfries C.G., Karlsson I., Oreland L. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology. 21:1999;372-379.
178. Prince J.A., Harro J., Blennow K., Gottfries C.G., Oreland L. Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schizophrenics. Neuropsychopharmacology. 22:2000;284-292.
179. Ramakers G.J., Avci B., van Hulten P., van Ooyen A., van Pelt J., Pool C.W., Lequin M.B. The role of calcium signaling in early axonal and dendritic morphogenesis of rat cerebral cortex neurons under non-stimulated growth conditions. Dev. Brain Res. 126:2001;163-172.
180. Rasolonjanahary R., Gerard C., Dufour M.N., Homburger V., Enjalbert A., Guillon G. Evidence for a direct negative coupling between dopamine-D2 receptors and PLC by heterotrimeric Gi1/2 proteins in rat anterior pituitary cell membranes. Endocrinology. 143:2002;747-754.
181. Redmond L., Kashani A.H., Ghosh A. Calcium regulation of dendritic growth via CaM kinase IV and CREB-mediated transcription. Neuron. 34:2002;999-1010.
182. Reynolds G.P., Zhang Z.J., Beasley C.L. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: selective losses of calcium binding protein immunoreactivity. Brain Res. Bull. 55:2001;579-584.
183. Rinaldi B., Di Pierro P., Vitelli M.R., D'Amico M., Berrino L., Rossi F., Filippelli A. Effects of docosahexaenoic acid on calcium pathway in adult rat cardiomyocytes. Life Sci. 71:2002;993-1004.
184. Ripova D., Strunecka A., Nemcova V., Farska I. Phospholipids and calcium alterations in platelets of schizophrenic patients. Physiol. Res. 46:1997;59-68.
185. Ristow M., Pfister M.F., Yee A.J., Schubert M., Michael L., Zhang C.Y., Ueki K., Michael M.D., Lowell B.B., Kahn C.R. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc. Natl. Acad. Sci. USA. 97:2000;12239-12243.
186. Rongo C., Kaplan J.M. CaMKII regulates the density of central glutamatergic synapses in vivo. Nature. 402:1999;195-199.
187. Rosenbaum G., Cohen B.D., Luby E.D., Gottlieb J.S., Yelen D. Comparison of Sernyl with other drugs. Arch. Gen. Psychiatry. 51:1995;651-656.
188. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gen. Psychiatry. 54:1997;487-494.
189. Ross B.M., Turenne S., Moszczynska A., Warsh J.J., Kish S.J. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res. 821:1999;407-413.
190. Saneyoshi T., Kume S., Amasaki Y., Mikoshiba K. The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature. 417:2002;295-299.
191. Sastry P.S., Rao K.S. Apoptosis and the nervous system. J. Neurochem. 74:2000;1-20.
192. 2+. J. Neurochem. 62:1994;916-922.
193. Sczekan S.R., Strumwasser F. Antipsychotic drugs block IP3-dependent Ca(2+)-release from rat brain microsomes. Biol. Psychiatry. 40:1996;497-502.
194. Segal M. Rapid plasticity of dendritic spine: hints to possible functions? Prog. Neurobiol. 63:2001;61-70.
195. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 45:1999;17-25.
196. Semeraro C., Ferrini R., Allievi L., Pocchiari F., Nicosia S., Casagrande C. Peripheral vascular and neuronal effects of dopamine receptor agonists. A comparison with receptor binding studies in rat striatum. Naunyn Schmiedebergs Arch. Pharmacol. 342:1990;539-546.
197. Sesack S.R., Bunney B.S. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. J. Pharmacol. Exp. Ther. 248:1989;1323-1333.
198. Sharp F.R., Butman M., Koistinaho J., Aardalen K., Nakki R., Massa S.M., Swanson R.A., Sagar S.M. Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience. 62:1994;1079-1092.
199. Skene J.H. GAP-43 as a 'calmodulin sponge' and some implications for calcium signalling in axon terminals. Neurosci. Res. 13:(Suppl.):1990;S112-S125.
200. Slemmon J.R., Feng B., Erhardt J.A. Small proteins that modulate calmodulin-dependent signal transduction: effects of PEP-19, neuromodulin, and neurogranin on enzyme activation and cellular homeostasis. Mol. Neurobiol. 22:2000;99-113.
201. Smalheiser N.R., Swanson D.R. Calcium-independent phospholipase A2 and schizophrenia. Arch. Gen. Psychiatry. 55:1998;752-753.
202. Smythies J.R. Oxidative reactions and schizophrenia: a review-discussion. Schizophr. Res. 24:1997;357-364.
203. r 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J. Neurosci. 18:1998;10297-10303.
204. Sobala G., Menzel E.J., Sinzinger H. Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem. Pharmacol. 61:2001;373-379.
205. Soria J.M., Valdeolmillos M. Receptor-activated calcium signals in tangentially migrating cortical cells. Cereb. Cortex. 12:2002;831-839.
206. Sower A.C., Bird E.D., Perrone-Bizzozero N.I. Increased levels of GAP-43 protein in schizophrenic brain tissues demonstrated by a novel immunodetection method. Mol. Chem. Neuropathol. 24:1995;1-11.
207. Sprengel R., Seeburg P.H. Ionotropic glutamate receptors. North A.R. Ligand and Voltage-Gated Channels. 1994;213-264 CRC Press, Boca Raton, FL.
208. Starkov A.A., Polster B.M., Fiskum G. Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax. J. Neurochem. 83:2002;220-228.
209. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71:2002;877-892.
210. Strunecka A., Ripova D. What can the investigation of phosphoinositide signaling system in platelets of schizophrenic patients tell us? Prostaglandins Leukot. Essent. Fatty Acids. 61:1999;1-5.
211. Studzinski D.M., Callahan R.E., Benjamins J.A. Increased intracellular calcium alters myelin gene expression in the N20.1 oligodendroglial cell line. J. Neurosci. Res. 57:1999;633-642.
212. Sun H.Q., Yamamoto M., Mejillano M., Yin H.L. Gelsolin, a multifunctional actin regulatory protein. J. Biol. Chem. 274:1999;33179-33182.
213. 2+, ErbB3, and phosphoinositide 3-kinase in 1321N1 astrocytoma cells. J. Biol. Chem. 277:2002;338-344.
214. Thierry A.M., Le Douarin C., Penit J., Ferron A., Glowinski J. Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex. Brain Res. Bull. 16:1986;155-160.
215. 2+ fit in? Cell Calcium. 24:1998;387-403.
216. Tolar L.A., Pallanck L. NSF function in neurotransmitter release involves rearrangement of the SNARE complex downstream of synaptic vesicle docking. J. Neurosci. 18:1998;10250-10256.
217. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., Nawa H. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 110:2002;249-257.
218. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42:2002;165-179.
219. Undie A.S., Friedman E. Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253:1990;987-992.
220. van Dam E.J., Ruiter B., Kamal A., Ramakers G.M., Gispen W.H., de Graan P.N. N-methyl-D-aspartate-induced long-term depression is associated with a decrease in postsynaptic protein kinase C substrate phosphorylation in rat hippocampal slices. Neurosci. Lett. 320:2002;29-132.
221. Vanhauwe J.F., Thomas T.O., Minshall R.D., Tiruppathi C., Li A., Gilchrist A., Yoon E.J., Malik A.B., Hamm H.E. Thrombin receptors activate G(o) proteins in endothelial cells to regulate intracellular calcium and cell shape changes. J. Biol. Chem. 277:2002;34143-34149.
222. Vawter M.P., Barrett T., Cheadle C., Sokolov B.P., Wood W.H. 3rd, Donovan D.M., Webster M., Freed W.J., Becker K.G. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 55:2001;641-650.
223. Vawter M.P., Crook J.M., Hyde T.M., Kleinman J.E., Weinberger D.R., Becker K.G., Freed W.J. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr. Res. 58:2002;11-20.
224. Vincent S.L., Khan Y., Benes F.M. Cellular colocalization of dopamine D1 and D2 receptors in rat medial prefrontal cortex. Synapse. 19:1995;112-120.
225. Vreugdenhil M., Bruehl C., Voskuyl R.A., Kang J.X., Leaf A., Wadman W.J. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc. Natl. Acad. Sci. USA. 93:1996;12559-12563.
226. Wang F., Bergson C., Howard R.L., Lidow M.S. Differential expression of D1 and D5 dopamine receptors in the fetal primate cerebral wall. Cereb. Cortex. 7:1997;711-721.
227. Wang H.Y., Undie A.S., Friedman E. Evidence for the coupling of Gq protein to D1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol. Pharmacol. 48:1995;988-994.
228. Wang J., Mayernik L., Schultz J.F., Armant D.R. Acceleration of trophoblast differentiation by heparin-binding EGF-like growth factor is dependent on the stage-specific activation of calcium influx by ErbB receptors in developing mouse blastocysts. Development. 127:2000;33-44.
229. Warburton E.C., Mitchell S.N., Joseph M.H. Calcium dependence of sensitised dopamine release in rat nucleus accumbens following amphetamine challenge: implications for the disruption of latent inhibition. Behav. Pharmacol. 7:1996;119-129.
230. Webster M.J., Shannon Weickert C., Herman M.M., Hyde T.M., Kleinman J.E. Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia. Schizophr. Res. 49:2001;89-98.
231. Weickert C.S., Webster M.J., Hyde T.M., Herman M.M., Bachus S.E., Bali G., Weinberger D.R., Kleinman J.E. Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cereb. Cortex. 11:2001;136-147.
232. Weinberger D.R., Berman K.F. Prefrontal function in schizophrenia: confounds and controversies. Phil. Trans. R. Soc. Lond. B Biol. Sci. 351:1996;1495-1503.
233. Weiss B., Prozialeck W.C., Wallace T.L. Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications. Biochem. Pharmacol. 31:1982;2217-2226.
234. Whatley S.A., Curti D., Marchbanks R.M. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem. Res. 21:1996;995-1004.
235. Wiesmann M., Wandinger K.P., Missler U., Eckhoff D., Rothermundt M., Arolt V., Kirchner H. Elevated plasma levels of S-100β protein in schizophrenic patients. Biol. Psychiatry. 45:1999;1508-1511.
236. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 376:1995;572-575.
237. Xing G., Chavko M., Zhang L.X., Yang S., Post R.M. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr. Res. 58:2002;21-30.
238. Xu X., Zeng W., Popov S., Berman D.M., Davignon I., Yu K., Yowe D., Offermanns S., Muallem S., Wilkie T.M. RGS proteins determine signaling specificity of Gq-coupled receptors. J. Biol. Chem. 274:1999;3549-3556.
239. Yang C.Q., Kitamura N., Nishino N., Shirakawa O., Nakai H. Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biol. Psychiatry. 43:1998;12-19.
240. Yang C.R., Seamans J.K., Gorelova N. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology. 21:1999;161-194.
241. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 15:2001;287-310.
242. Yarlagadda A. Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions. Med. Hypotheses. 58:2002;182-186.
243. Yesavage J.A., Freman A.M. Acute phencyclidine (PCP) intoxication: psychopathology and prognosis. J. Clin. Psychiatry. 39:1978;664-666.
244. Yin Y., Dayanithi G., Lemos J.R. Ca(2+)-regulated, neurosecretory granule channel involved in release from neurohypophysial terminals. J. Physiol. 539:2002;409-418.
245. Zhou S., Heller L.J., Wallace K.B. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol. Appl. Pharmacol. 175:2001;60-67.